Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.

Xiao, Xian; Zhang, Guixing; Sun, Binxu; Wang, Chaoran; Wang, Xiaoqun; Kong, Fanming; Jia, Yingjie

Xiao, Xian; Zhang, Guixing; Sun, Binxu; Wang, Chaoran; Wang, Xiaoqun; Kong, Fanming; Jia, Yingjie.

Afiliación

Xiao X; Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Zhang G; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Sun B; Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Wang C; Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Wang X; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Kong F; Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Jia Y; Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Transl Cancer Res ; 11(6): 1472-1482, 2022 Jun.

Article en En | MEDLINE | ID: mdl-35836506

Palabras clave

Bevacizumab; biosimilar; meta-analysis; non-squamous non-small cell lung cancer (non-squamous NSCLC); randomized controlled trial (RCT)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Transl Cancer Res Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google